The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: a systematic review and meta-analysis

References

• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999;10: 1419–1432.
   PubMed Web of Science ®Google Scholar
• Chan JKC, Quintanilla-Martinez L, Ferry JA. Extranodal NK/ T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NK, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, Lyon: IARC Press; 2008. pp 285–288.
   Google Scholar
• Li L, Liu YH, Zhuang HG, et al. Extranodal nasal type NK/T-cell lymphoma: clinicopathologic and prognostic study of 55 cases. Zhonghua Bing Li Xue Za Zhi 2009;38:237–242.
   PubMedGoogle Scholar
• Sandner A, Kosling S, Helmbold P, et al. Primary nasal natural killer/T-cell lymphomas: classification and clinicopathological features. HNO 2007;55:93–99.
   PubMed Web of Science ®Google Scholar
• Li S, Feng X, Li T, et al. Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol 2013;37:14–23.
   PubMed Web of Science ®Google Scholar
• Metgud RS, Doshi JJ, Gaurkhede S, et al. Extranodal NK/T-cell lymphoma, nasal type (angiocentric T-cell lymphoma): a review about the terminology. J Oral Maxillofac Pathol 2011;15:96–100.
   PubMedGoogle Scholar
• Cho EY, Kim KH, Kim WS, et al. The spectrum of Epstein-Barr virus-associated lymphoproliferative disease in Korea: incidence of disease entities by age groups. J Korean Med Sci 2008;23:185–192.
   PubMed Web of Science ®Google Scholar
• Bugalia A, Manipadam MT, Nair S. Immunomorphologic profile and Epstein-Barr virus status of a cohort of 35 cases of extranodal natural killer/T-cell lymphoma, nasal type of upper aerodigestive tract from a tertiary care center in South India. Leuk Lymphoma 2012;54:1201–1207.
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931–3937.
   PubMed Web of Science ®Google Scholar
• Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005;41:1402–1408.
   PubMed Web of Science ®Google Scholar
• Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009;15:2905–2912.
   PubMed Web of Science ®Google Scholar
• Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004;100:366–375.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Abouyabis AN, Shenoy PJ, Lechowicz MJ, et al. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008;49:2099–2107.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002–1006.
   PubMed Web of Science ®Google Scholar
• dos Santos LV, Lima JP, Lima CS, et al. Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis. BMC Cancer 2012;12:288.
   PubMed Web of Science ®Google Scholar
• Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2009;2:14.
   PubMed Web of Science ®Google Scholar
• Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control 2012;19:204–213.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032–3038.
   PubMed Web of Science ®Google Scholar
• Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197–204.
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54:182–190.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim BS, Choi CW, et al. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma 2006;47: 1265–1273.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Li YX, Wang H, et al. Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma. Ann Oncol 2011;22:390–396.
   PubMed Web of Science ®Google Scholar
• Wang L, Xia ZJ, Huang HQ, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol 2012;96:617–623.
   PubMed Web of Science ®Google Scholar
• Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005;106: 3785–3790.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612–618.
   PubMed Web of Science ®Google Scholar
• You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004;15:618–625.
   PubMed Web of Science ®Google Scholar
• Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 2008;70:166–174.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim WS, Park YH, et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 2005;92: 1226–1230.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Ell Hajj M, Janot F, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001;15:1123–1126.
   PubMed Web of Science ®Google Scholar
• Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998;339:21–26.
   PubMed Web of Science ®Google Scholar
• Li YX, Wang H, Jin J, et al. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2012;82:1809–1815.
   PubMed Web of Science ®Google Scholar
• Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006;106:609–615.
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181–189.
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000;18:54–63.
   PubMed Web of Science ®Google Scholar
• Li YX, Liu QF, Wang WH, et al. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy. Cancer 2011;117:5203–5211.
   PubMed Web of Science ®Google Scholar
• Guo Y, Lu JJ, Ma X, et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol 2008;44:23–30.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 2013;119:348–355.
   PubMed Web of Science ®Google Scholar
• Wu X, Li P, Zhao J, et al. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clin Oncol (R Coll Radiol) 2008;20:619–625.
   PubMed Web of Science ®Google Scholar
• Wang B, Lu JJ, Ma X, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity. Leuk Lymphoma 2007;48:396–402.
   PubMed Web of Science ®Google Scholar
• Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma. Ann Oncol 2001;12:349–352.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. Quality assessment scales for observational studies. Ottowa Health Research Institute. 2004. Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.htm
   Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820–826.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101.
   PubMed Web of Science ®Google Scholar
• Gui W, Zhao Z, Shen Q, et al. The clinical study of extranodal natural killer cell lymphoma, nasal type. Med Oncol 2011;28 (Suppl. 1):S367–S372.
   PubMed Web of Science ®Google Scholar
• Zhang SS, Wei M, Li HH, et al. Therapy and prognosis analysis of 47 patients with extranodal NK/T-cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011;19:119–123.
   PubMedGoogle Scholar
• Barrionuevo C, Zaharia M, Martinez MT, et al. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 2007;15:38–44.
   PubMedGoogle Scholar
• Lee J, Cho SG, Chung SM, et al. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL). Ann Hematol 2012;92:333–343.
   PubMed Web of Science ®Google Scholar
• Yao B, Li YX, Fang H, et al. Prognostic factors and treatment outcome in early stage nasal NK/T cell lymphoma. Zhonghua Xue Ye Xue Za Zhi 2006;27:222–225.
   PubMedGoogle Scholar
• Frata P, Buglione M, Grisanti S, et al. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution. Tumori 2005;91:456–462.
   PubMed Web of Science ®Google Scholar
• Hatta C, Ogasawara H, Okita J, et al. Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification. Auris Nasus Larynx 2001;28: 55–60.
   PubMed Web of Science ®Google Scholar
• Kim GE, Lee SW, Chang SK, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001;61:261–269.
   PubMed Web of Science ®Google Scholar
• Kim K, Chie EK, Kim CW, et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 2005;35:1–5.
   PubMed Web of Science ®Google Scholar
• Ma HH, Qian LT, Pan HF, et al. Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/ T-cell lymphoma. Med Oncol 2010;27:798–806.
   PubMed Web of Science ®Google Scholar
• Tham IW, Lee KM, Yap SP, et al. Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head Neck 2006;28:126–134.
   PubMed Web of Science ®Google Scholar
• Luo YK, Tan Y, Fu BY, et al. Prognostic factors and curative efficacy of nasal NK/T-cell lymphoma. China Mod Doctor 2010;48:26–27.
   Google Scholar
• Chen J, Guo JX, Tao QS, et al. Effect of radiotherapy in 20 cases with nasal NK/T-cell lymphoma. J Oncol 2007;13:2231–232.
   Google Scholar
• Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 2008;112:3057–3064.
   PubMed Web of Science ®Google Scholar
• Chauchet A, Michallet AS, Berger F, et al. Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J Hematol Oncol 2012;5:27.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Lee SW, Suh C, et al. Treatment outcome of nasal natural killer/T-cell lymphoma. Radiat Oncol J 2011;29:174–180.
   Google Scholar
• Zheng NY, Shao XF, Mo ZW, et al. An analysis of treatment outcome and prognosis on early stage natural killer/T cell lymphoma, nasal type. China Med Pharm 2012;2:40–41.
   Google Scholar
• Zhao YL, Li QM, Tan XB, et al. An analysis of pathologic diagnosis and clinical therapy on 55 patients with natural killer/T cell lymphoma. China Med Pharm 2011;18:5–7.
   Google Scholar
• Dai J, Yang SL, Zhu JH, et al. The preliminary effecacy of 3D conformal radiotherapy combined with chemotherapy for early stage NK/T-cell lymphoma. World Health Dig Med Period 2012;9:172–173.
   Google Scholar
• Kim BS, Kim TY, Kim CW, et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 2003;42:779–783.
   PubMed Web of Science ®Google Scholar
• Kim GE, Yang WI, Lee SW, et al. Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma 2004;45:1857–1864.
   PubMed Web of Science ®Google Scholar
• Jung CK, Lee KY, Kim Y, et al. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int 2001;51:355–363.
   PubMed Web of Science ®Google Scholar
• Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol 2008;83: 795–799.
   PubMed Web of Science ®Google Scholar
• Huang WT, Huang CC, Weng SW, et al. Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene. Pathology 2009;41:127–132.
   PubMed Web of Science ®Google Scholar
• Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008;14:1356–1364.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410–4416.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012;48:3223–3231.
   PubMed Web of Science ®Google Scholar
• Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol 2010;92: 697–701.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008;19:2079–2083.
   PubMed Web of Science ®Google Scholar
• Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 2005;130:860–868.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117:1834–1839.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhu J, et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009;88:647–652.
   PubMed Web of Science ®Google Scholar
• Hu QY, Liu P. Prognositc factors and curative efficacy in 84 cases with NK/T-cell lymphoma, nasal type. J Pract Oncol 2007;22:317–321.
   Google Scholar